Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects (Q79226756)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035934%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035934%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

Karen L Houseknecht

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035934%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Alan S Robertson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035934%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

William Zavadoski

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035934%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

E Michael Gibbs

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035934%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

David E Johnson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035934%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Hans Rollema

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035934%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

11 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035934%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

published in

Neuropsychopharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035934%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035934%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035934%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

289-297

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17035934%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.npp.1301209

20 December 2019

exact match

0 references

cites work

Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Insulin signal transduction in human skeletal muscle: identifying the defects in Type II diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Epinephrine-induced insulin resistance in man.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Nitric oxide stimulates skeletal muscle glucose transport through a calcium/contraction- and phosphatidylinositol-3-kinase-independent pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Nervous control of liver metabolism and hemodynamics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Schizophrenia, the metabolic syndrome and diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Olanzapine-associated diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Clozapine-associated diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Role of central neural mechanisms in the regulation of hepatic glucose metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

At therapeutic concentrations, olanzapine does not affect basal or insulin-stimulated glucose transport in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Mechanism by which hyperglycemia inhibits hepatic glucose production in conscious rats. Implications for the pathophysiology of fasting hyperglycemia in diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Undiagnosed hyperglycemia in patients treated with atypical antipsychotics.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021

Acetylcholine affects rat liver metabolism via type 3 muscarinic receptors in hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301209

7 January 2021